Thymosin Alpha-1 vs LL-37
Thymic immunomodulatory peptide vs human cathelicidin antimicrobial peptide — adaptive vs innate immune system enhancement.
Last updated: 2026-03-08
Quick Comparison Table
| Category | Thymosin Alpha-1 | LL-37 |
|---|---|---|
| Origin | Thymus gland (28 amino acids) | Human cathelicidin (37 amino acids) |
| Primary Mechanism | T-cell maturation, dendritic cell activation | Direct antimicrobial, innate immune activation |
| Immune Branch | Adaptive immunity (T-cells, NK cells) | Innate immunity (antimicrobial, barrier defence) |
| Approval Status | Approved in 35+ countries (Zadaxin) | Research peptide (not approved) |
| Administration | SC injection | SC injection, topical |
| Clinical Use | Hepatitis B/C, immunodeficiency, cancer adjunct | Antimicrobial research, wound healing |
| Anti-Cancer | Immunotherapy adjuvant (enhances checkpoint inhibitors) | Direct anti-tumour activity + immune modulation |
| Key Advantage | 35+ years clinical use, strong safety record | Broad-spectrum antimicrobial without resistance |
Mechanism of Action
Thymosin Alpha-1
Thymosin Alpha-1 Mechanism:
Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide originally isolated from thymic tissue by Allan Goldstein in 1977. It is the primary immunoactive component of Thymosin Fraction 5.
Key actions: 1. **T-cell maturation** — Promotes differentiation of immature thymocytes into functional T-cells 2. **Dendritic cell activation** — Enhances antigen presentation and Th1 polarisation 3. **NK cell activation** — Increases natural killer cell cytotoxicity 4. **TLR signalling** — Acts through Toll-like receptors (TLR2, TLR9) as an innate-adaptive bridge 5. **Anti-inflammatory balance** — Promotes immune response without excessive inflammation
Tα1 is particularly effective in immunocompromised patients — restoring immune function without causing autoimmunity or excessive inflammation.
LL-37
LL-37 Mechanism:
LL-37 is the only human cathelicidin antimicrobial peptide — a 37-amino acid amphipathic α-helical peptide cleaved from the precursor hCAP18.
Key actions: 1. **Direct antimicrobial** — Disrupts bacterial, viral, and fungal membranes through electrostatic interaction 2. **Biofilm disruption** — Penetrates and disperses bacterial biofilms 3. **Immune cell chemotaxis** — Recruits neutrophils, monocytes, and T-cells to infection sites 4. **Wound healing** — Promotes re-epithelialisation and angiogenesis 5. **Anti-endotoxin** — Neutralises LPS, reducing sepsis-related inflammation 6. **Anti-viral** — Direct virucidal activity and enhanced interferon responses
LL-37 is a front-line innate immune effector — the body's first response to microbial invasion.
Clinical Trial Evidence
Thymosin Alpha-1 Clinical Studies
Participants: 435
Duration: 52 weeks
Tα1 1.6mg SC twice weekly achieved sustained virological response in 40% of HBV patients vs 20% placebo.
Statistically significant
Participants: 210
Duration: 48 weeks
Tα1 + IFN-α improved SVR rates to 52% vs 34% with IFN-α alone in HCV genotype 1.
Statistically significant
Participants: 361
Duration: 28 days
Tα1 reduced 28-day mortality from 35% to 26% in severe sepsis (HR 0.62). Improved HLA-DR expression.
Statistically significant
Participants: 80
Duration: 6 months
Tα1 combined with PD-1 inhibitor improved objective response rate in NSCLC: 42% vs 24% with PD-1 alone.
Statistically significant
Participants: 76
Duration: 14 days
Tα1 reduced mortality in critically ill COVID-19 patients with lymphopenia: 11.1% vs 30% in control group.
Statistically significant
LL-37 Clinical Studies
Participants: 20
Duration: 4 weeks
Topical LL-37 accelerated healing of chronic venous leg ulcers. 50% achieved >50% wound area reduction vs 25% placebo.
Statistically significant
Participants: 0
Duration: In vitro
LL-37 disrupted established Staphylococcus and Pseudomonas biofilms at sub-MIC concentrations.
Statistically significant
Participants: 0
Duration: In vitro/In vivo
LL-37 showed direct virucidal activity against influenza A and enhanced interferon-mediated antiviral responses.
Statistically significant
Participants: 146
Duration: 36 weeks
Vitamin D supplementation increased LL-37 production and improved tuberculosis treatment outcomes. Mechanistic link confirmed.
Statistically significant
Participants: 0
Duration: In vivo (mice)
LL-37 analogue inhibited colorectal tumour growth by 40% through direct anti-tumour and immune-stimulatory mechanisms.
Statistically significant
Benefits Comparison
Thymosin Alpha-1 Unique Benefits
- Approved drug in 35+ countries
- Proven efficacy in hepatitis B/C
- Sepsis mortality reduction
- Cancer immunotherapy enhancement
- Decades of clinical safety data
Shared Benefits
- Immune system enhancement
- Anti-cancer potential
- Anti-inflammatory properties
- Infection response improvement
LL-37 Unique Benefits
- Broad-spectrum antimicrobial (bacteria, viruses, fungi)
- Biofilm disruption
- Low resistance development risk
- Wound healing promotion
- Endogenous molecule (vitamin D-regulated)
Research & Evidence
Thymosin Alpha-1 Research
Thymosin Alpha-1 has been studied in 100+ clinical trials with thousands of patients. Zadaxin is approved in 35+ countries for hepatitis B, and has extensive data in hepatitis C, sepsis, cancer immunotherapy, and immunodeficiency.
LL-37 Research
LL-37 research is primarily preclinical. Human data is limited to small wound healing studies and observational vitamin D-LL-37 correlation studies. No large-scale clinical trials have been completed for therapeutic LL-37 administration.
Head-to-Head Analysis
Complementary Roles:
Thymosin Alpha-1 and LL-37 operate on different branches of immunity: - Tα1: Adaptive immunity — training and activating T-cells for specific pathogen recognition - LL-37: Innate immunity — immediate, broad-spectrum antimicrobial defence
In a sequential immune response, LL-37 acts first (killing pathogens directly, recruiting immune cells), while Tα1 strengthens the adaptive response that follows (T-cell activation, immunological memory).
Evidence Quality: Tα1 has a vastly larger clinical evidence base — approved in 35+ countries with decades of use in hepatitis, cancer, and immunodeficiency. LL-37 is primarily preclinical with limited human data.
Protocol Comparison
Thymosin Alpha-1 Protocol
Thymosin Alpha-1 (Zadaxin) Clinical Protocols:
Hepatitis B: 1.6mg SC twice weekly for 6-12 months. Immunodeficiency: 1.6mg SC 2-3x weekly. Cancer Adjunct: 1.6mg SC daily during active immunotherapy. Sepsis: 1.6mg SC twice daily for 5-7 days.
Route: SC injection.
LL-37 Protocol
LL-37 Theoretical Protocols (Research-Based):
Topical (Wound Healing): 0.5-3.2 mg/ml topical gel or solution applied to wound.
Systemic (Research): SC injection doses not well-established. Limited to investigational use.
⚠️ Disclaimer: No approved therapeutic protocol exists for systemic LL-37.
Safety Profiles
Thymosin Alpha-1 Safety
Thymosin Alpha-1 Safety:
Excellent safety profile over 35+ years. Common: mild injection site reactions. No immunosuppression, no autoimmunity induction, no organ toxicity. Safe in elderly and immunocompromised patients. One of the best-tolerated immunotherapeutic agents available.
LL-37 Safety
LL-37 Safety:
Limited human safety data. Topical use well-tolerated. Systemic administration safety is largely unknown.
Theoretical concerns: At high concentrations, LL-37 can be cytotoxic to host cells (not just microbes). Pro-inflammatory at high doses. Potential to exacerbate autoimmune conditions (psoriasis involves LL-37 dysregulation).
The Verdict
Thymosin Alpha-1 is the clinically validated choice for immune enhancement — approved in 35+ countries with decades of data in hepatitis, sepsis, and cancer immunotherapy. LL-37 represents an exciting but early-stage approach to innate immunity and antimicrobial defence. They are mechanistically complementary — Tα1 for adaptive immunity, LL-37 for innate defence — and their combination has been explored in peptide stack research. For current clinical use, Tα1 is the established standard.
Frequently Asked Questions
Conclusion
Thymosin Alpha-1 and LL-37 complement each other across the adaptive-innate immune spectrum. Tα1's 35+ year clinical track record, regulatory approvals, and proven efficacy in serious infections and cancer make it the established immunotherapeutic peptide. LL-37's unique broad-spectrum antimicrobial and biofilm-disrupting properties offer a different angle on immune support that is still being translated into clinical applications. Together, they represent a comprehensive peptide approach to immune optimisation.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither Thymosin Alpha-1 nor LL-37 is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.